Expression profiles of gastric cancer molecular subtypes in remnant tumors

被引:1
作者
Kodama Pertille Ramos, Marcus Fernando [1 ]
Pereira, Marina Alessandra [1 ]
Cardili, Leonardo [2 ]
de Mello, Evandro Sobroza [2 ]
Ribeiro Jr, Ulysses [1 ]
Zilberstein, Bruno [1 ]
Cecconello, Ivan [1 ]
机构
[1] Univ Sao Paulo, Dept Gastroenterol, Inst Canc, Hosp Clin,HCFMUSP,Fac Med, 251 Av Dr Arnaldo, BR-01249000 Sao Paulo, SP, Brazil
[2] Univ Sao Paulo, Hosp Clin, Fac Med, Dept Pathol,Inst Canc,HCFMUSP, BR-01249000 Sao Paulo, SP, Brazil
关键词
Stomach neoplasms; Gastric remnant; Gastric remnant cancer; Adenocarcinoma; Immunohistochemistry; EPSTEIN-BARR-VIRUS; DISTAL GASTRECTOMY; RETROSPECTIVE ANALYSIS; PROGNOSTIC-FACTORS; STUMP CARCINOMA; STOMACH;
D O I
10.4251/wjgo.v13.i4.265
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Remnant gastric cancer (RGC) is a carcinoma arising in the stomach remnant after previous gastric resection. It is frequently reported as a tumor with a poor prognosis and distinct biological features from primary gastric cancer (PGC). However, as it is less frequent, its profile regarding the current molecular classifications of gastric cancer has not been evaluated. AIM To evaluate a cohort of RGC according to molecular subtypes of GC using a panel of immunohistochemistry and in situ hybridization to determine whether the expression profile is different between PGC and RGC. METHODS Consecutive RGC patients who underwent gastrectomy between 2009 and 2019 were assessed using seven GC panels: Epstein-Barr virus in situ hybridization, immunohistochemistry for mismatch repair proteins (MutL homolog 1, MutS homolog 2, MutS homolog 6, and PMS1 homolog 2), p53 protein, and E-cadherin expression. Clinicopathological characteristics and survival of these patients were compared to 284 PGC patients. RESULTS A total of 40 RGC patients were enrolled in this study. Compared to PGC, older age (P < 0.001), male (P < 0.001), lower body mass index (P = 0.010), and lower hemoglobin level (P < 0.001) were associated with RGC patients. No difference was observed regarding Lauren's type and pathologic Tumor Node Metastasis stage between the groups. Regarding the profiles evaluated, EBV-positive tumors were higher in RGC compared to PGC (P = 0.039). The frequency of microsatellite instability, aberrant p53 immunostaining, and loss of E-cadherin expression were similar between RGC and PGC. Higher rates of simultaneous alterations in two or more profiles were observed in RGC compared to PGC (P < 0.001). According to the molecular classification, the subtypes were defined as EBV in nine (22.5%) cases, microsatellite instability in nine (22.5%) cases, genomically stable in one (2.5%) case, and chromosomal instability in 21 (52.5%) cases. There was no significant difference in survival between molecular subtypes in RGC patients. CONCLUSION RGC was associated with EBV positivity and higher rates of co-altered expression profiles compared to PGC. According to the molecular classification, there was no significant difference in survival between the subtypes of RGC.
引用
收藏
页码:265 / 278
页数:14
相关论文
共 35 条
  • [1] Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
    Aguirre, Andrew J.
    Hruban, Ralph H.
    Raphael, Benjamin J.
    [J]. CANCER CELL, 2017, 32 (02) : 185 - +
  • [2] High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications
    Ahn, Sangjeong
    Lee, So-Jeong
    Kim, Yonugkeum
    Kim, Ahrong
    Shin, Nari
    Choi, Kyung Un
    Lee, Chang-Hun
    Huh, Gi Yeong
    Kim, Kyong-Mee
    Setia, Namrata
    Lauwers, Gregory Y.
    Park, Do Youn
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (01) : 106 - 115
  • [3] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
    Amin, Mahul B.
    Greene, Frederick L.
    Edge, Stephen B.
    Compton, Carolyn C.
    Gershenwald, Jeffrey E.
    Brookland, Robert K.
    Meyer, Laura
    Gress, Donna M.
    Byrd, David R.
    Winchester, David P.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) : 93 - 99
  • [4] Aya M, 2006, ANTICANCER RES, V26, P1403
  • [5] Paranuclear E-cadherin in gastric adenocarcinoma
    Carpenter, PM
    Al-Kuran, RA
    Theuer, CP
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (06) : 887 - 894
  • [6] Cecconello I., 2020, REV COL BRAS CIR, V47
  • [7] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [8] TP53 and gastric carcinoma: A review
    Fenoglio-Preiser, CM
    Wang, J
    Stemmermann, GN
    Noffsinger, A
    [J]. HUMAN MUTATION, 2003, 21 (03) : 258 - 270
  • [9] Guidelines and considerations for conducting experiments using tissue microarrays
    Ilyas, Mohammad
    Grabsch, Heike
    Ellis, Ian O.
    Womack, Chris
    Brown, Robert
    Berney, Dan
    Fennell, Dean
    Salto-Tellez, Manuel
    Jenkins, Martin
    Landberg, Goran
    Byers, Richard
    Treanor, Darren
    Harrison, David
    Green, Andrew R.
    Ball, Graham
    Hamilton, Peter
    [J]. HISTOPATHOLOGY, 2013, 62 (06) : 827 - 839
  • [10] Imada T, 1998, ANTICANCER RES, V18, P231